diclofenac has been researched along with Pancreatitis in 63 studies
Diclofenac: A non-steroidal anti-inflammatory agent (NSAID) with antipyretic and analgesic actions. It is primarily available as the sodium salt.
diclofenac : A monocarboxylic acid consisting of phenylacetic acid having a (2,6-dichlorophenyl)amino group at the 2-position.
Pancreatitis: INFLAMMATION of the PANCREAS. Pancreatitis is classified as acute unless there are computed tomographic or endoscopic retrograde cholangiopancreatographic findings of CHRONIC PANCREATITIS (International Symposium on Acute Pancreatitis, Atlanta, 1992). The two most common forms of acute pancreatitis are ALCOHOLIC PANCREATITIS and gallstone pancreatitis.
| Excerpt | Relevance | Reference |
|---|---|---|
| "High-dose rectal diclofenac suppository and epinephrine spray on duodenal papilla during endoscopic retrograde cholangiopancreatography (ERCP) may reduce the incidence of post-ERCP pancreatitis." | 9.41 | Randomized trial of high-dose rectal diclofenac suppository and epinephrine spray on duodenal papilla for prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis. ( Ashraf, A; Dar, HA; Javid, G; Khan, MA; Mohammad, S; Shah, A; Sheikh, NA; Singh, B, 2021) |
| "Both diclofenac and tramadol are equally effective in controlling pain in AP with similar safety profile." | 9.34 | Comparison of efficacy of diclofenac and tramadol in relieving pain in patients of acute pancreatitis: A randomized parallel group double blind active controlled pilot study. ( Dhaka, N; Gupta, V; Kochhar, R; Kumar, NS; Muktesh, G; Samanta, J; Samra, T; Sarma, P; Sinha, SK; Yadav, TD, 2020) |
| "We aimed to compare the efficacy of prophylactic, parenterally administered ceftazidime and rectally applied diclofenac sodium for the prophylaxis of post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP)." | 9.24 | Diclofenac sodium versus ceftazidime for preventing pancreatitis after endoscopic retrograde cholangiopancreatography: a prospective, randomized, controlled trial. ( Blažević, I; Bulić, Z; Giljača, V; Hauser, G; Poropat, G; Salkić, N; Štimac, D, 2017) |
| "Prophylaxis with diclofenac given rectally or intramuscularly is an effective option for the management of post-ERCP pancreatitis." | 9.22 | Rectal or intramuscular diclofenac reduces the incidence of pancreatitis afterendoscopic retrograde cholangiopancreatography. ( Ataseven, H; Biyik, M; Çifçi, S; Demir, A; Polat, İ; Uçar, E; Uçar, R, 2016) |
| "We aimed to investigate the preventive effect of oral diclofenac on pancreatitis after ERCP in a multicenter, randomized, prospective, placebo-controlled, double-blind trial." | 9.22 | No Benefit of Oral Diclofenac on Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis. ( Doi, S; Hayashi, T; Hisai, H; Ishiwatari, H; Iwashita, T; Kato, J; Kawakami, H; Kawakubo, K; Matsusaki, S; Ono, M; Sakamoto, N; Sonoda, T; Urata, T; Yasuda, I, 2016) |
| "Combination therapy with udenafil and aceclofenac is not effective for the prevention of post-ERCP pancreatitis." | 9.20 | Oral udenafil and aceclofenac for the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis in high-risk patients: a randomized multicenter study. ( Cheon, YK; Choi, JS; Do, JH; Lee, TY; Oh, HC; Song, TJ, 2015) |
| "To assess the efficacy of intramuscular diclofenac and fluid replacement for prevention of post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis." | 9.14 | Efficacy of intramuscular diclofenac and fluid replacement in prevention of post-ERCP pancreatitis. ( Demirkan, H; Saritas, U; Senol, A, 2009) |
| "This trial shows that rectal diclofenac given immediately after endoscopic retrograde cholangiopancreatography can reduce the incidence of acute pancreatitis." | 9.13 | Role of diclofenac in reducing post-endoscopic retrograde cholangiopancreatography pancreatitis. ( Ehsani Ardakani, MJ; Farzin, H; Khorram, H; Khoshbaten, M; Madad, L; Zali, MR, 2008) |
| "The aim of this study was to determine whether prophylactic oral diclofenac will reduce the incidence and the severity of ERCP-induced pancreatitis, especially in high-risk patients." | 9.12 | Efficacy of diclofenac in the prevention of post-ERCP pancreatitis in predominantly high-risk patients: a randomized double-blind prospective trial. ( Cheon, YK; Cho, KB; Fogel, EL; Lazzell-Pannell, L; Lehman, GA; McHenry, L; Schmidt, S; Sherman, S; Watkins, JL, 2007) |
| "This trial shows that rectal diclofenac given immediately after endoscopic retrograde cholangiopancreatography can reduce the incidence of acute pancreatitis." | 9.10 | Diclofenac reduces the incidence of acute pancreatitis after endoscopic retrograde cholangiopancreatography. ( Carter, R; Evans, S; Imrie, C; Murray, B; O'Suilleabhain, C, 2003) |
| "Diclofenac and indomethacin are the most studied drugs for preventing post-ERCP pancreatitis (PEP)." | 8.95 | Indomethacin and diclofenac in the prevention of post-ERCP pancreatitis: a systematic review and meta-analysis of prospective controlled trials. ( Mohácsi, L; Patai, Á; Patai, ÁV; Solymosi, N, 2017) |
| "We evaluated the preventive effect of low-dose diclofenac (25-50 mg) on post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP) by propensity score matching analysis." | 8.02 | Rectally Administered Low-Dose Diclofenac Has No Effect on Preventing Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis: A Propensity Score Analysis. ( Hori, Y; Ikeura, T; Ito, T; Masuda, M; Mitsuyama, T; Miyoshi, H; Naganuma, M; Nakamaru, K; Okazaki, K; Shimatani, M; Takaoka, M; Takaori, A, 2021) |
| "In this work, no benefit was obtained with diclofenac plus hydration in reducing the number and severity of cases of post-ERCP pancreatitis nor with the other prophylactic measures." | 8.02 | Hydration with Lactated Ringer's solution combined with rectal diclofenac in the prevention of pancreatitis after endoscopic retrograde cholangiopancreatography. ( Almaraz-Gómez, A; Del Olmo Martínez, ML; Velayos Jiménez, B, 2021) |
| "A 50-100 mg rectal dose of diclofenac or indomethacin is recommended for prophylaxis of post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP); however, limited data are available regarding the appropriate dose to prevent PEP in elderly patients." | 8.02 | A 25 mg rectal dose of diclofenac for prevention of post-ERCP pancreatitis in elderly patients. ( Fujiwara, Y; Fukuda, T; Higashimori, A; Ikeda, D; Maeda, N; Maruyama, H; Mizuno, Y; Morimoto, K; Nakamura, Y; Nakatani, M; Watanabe, T, 2021) |
| "In this large patient cohort in a low-risk unit, diclofenac does not seem to reduce the risk of post-ERCP pancreatitis in patients with PSC." | 7.96 | Diclofenac does not reduce the risk of acute pancreatitis in patients with primary sclerosing cholangitis after endoscopic retrograde cholangiography. ( Färkkilä, M; Jokelainen, K; Koskensalo, V; Kylänpää, L; Lindström, O; Rainio, M; Tenca, A; Udd, M, 2020) |
| "Objective A 50-100-mg rectal dose of nonsteroidal anti-inflammatory drugs (NSAIDs; diclofenac or indomethacin) has been shown to prevent post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP)." | 7.88 | The Effectiveness of the Rectal Administration of Low-dose Diclofenac for the Prevention of Post-endoscopic Retrograde Cholangiopancreatography Pancreatitis. ( Imai, S; Okuno, M; Sato, H; Shiroko, J; Taguchi, D; Takada, J; Thanabashi, S; Yamaguchi, K, 2018) |
| "rectal diclofenac is a nonsteroidal anti-inflammatory drug (NSAID) that is used to prevent pancreatitis in high-risk patients during endoscopic retrograde cholangiopancreatography (ERCP)." | 7.88 | Rectal diclofenac does not prevent post-ERCP pancreatitis in consecutive high-risk and low-risk patients. ( Almaraz Gómez, A; Del Olmo Martínez, L; Velayos Jiménez, B, 2018) |
| "Our aim was to evaluate the effect of diclofenac in preventing post-ERCP pancreatitis (PEP) in a high-volume, low-PEP-risk ERCP unit." | 7.85 | Diclofenac Does Not Reduce the Risk of Post-endoscopic Retrograde Cholangiopancreatography Pancreatitis in Low-Risk Units. ( Kylänpää, L; Lindström, O; Louhimo, J; Rainio, M; Udd, M, 2017) |
| "High patient body weight was associated with a reduced effect of 100 mg diclofenac for prophylaxis of PEP." | 7.83 | Effect of body weight on fixed dose of diclofenac for the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis. ( Hansen, MB; Jørgensen, LN; Leerhøy, B; Nordholm-Carstensen, A; Novovic, S, 2016) |
| "This controlled cohort study suggests that the implementation of a single dose of 100 mg of diclofenac rectally administered significantly reduces the incidence of post-ERCP pancreatitis in an unselected material of patients with native papilla." | 7.80 | Diclofenac is associated with a reduced incidence of post-endoscopic retrograde cholangiopancreatography pancreatitis: results from a Danish cohort study. ( Hansen, MB; Jørgensen, LN; Leerhøy, B; Nordholm-Carstensen, A; Novovic, S, 2014) |
| "A 34 year old female developed acute pancreatitis after commencing diclofenac for a painful arthropathy." | 7.68 | Pancreatitis associated with diclofenac. ( Edward, N; Khan, IH, 1993) |
| "Post-ERCP pancreatitis is usually mild to moderate 95% times." | 7.01 | Is the Combination of Rectal Diclofenac and Intravenous Ringer Lactate Superior to Individual Therapy for Prophylaxis of Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis: A Prospective, Open-Label, Single-Center Randomized Trial. ( Chandnani, S; Debnath, P; Jain, S; Nair, S; Rathi, P; Thanage, R; Udgirkar, S, 2021) |
| "Acute pancreatitis is a major adverse event of endoscopic retrograde cholangiopancreatography (ERCP)." | 6.90 | Combination of Diclofenac and Sublingual Nitrates Is Superior to Diclofenac Alone in Preventing Pancreatitis After Endoscopic Retrograde Cholangiopancreatography. ( Akimoto, Y; Fujii, M; Harada, R; Hata, H; Kato, H; Kawai, Y; Matsubara, M; Ogawa, T; Okada, H; Takatani, M; Tomoda, T; Ueki, T; Wato, M, 2019) |
| "Fentanyl was given as a rescue analgesic through a patient-controlled analgesia pump." | 6.90 | Pentazocine, a Kappa-Opioid Agonist, Is Better Than Diclofenac for Analgesia in Acute Pancreatitis: A Randomized Controlled Trial. ( Bopanna, S; Garg, PK; Gupta, S; Jain, S; Mahapatra, SJ; Singh, P; Sreenivas, V; Trikha, A, 2019) |
| "Acute pancreatitis is one of the most common complications of endoscopic retrograde cholangiopancreatography (ERCP)." | 6.79 | Effect of diclofenac on the levels of lipoxin A4 and Resolvin D1 and E1 in the post-ERCP pancreatitis. ( Bao, JJ; Ding, H; Hu, C; Liu, XC; Mei, Q; Xu, JM; Zhao, XW, 2014) |
| "Acute pancreatitis is a common complication of endoscopic retrograde cholangiopancreatography (ERCP)." | 6.77 | Low-dose rectal diclofenac for prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: a randomized controlled trial. ( Akiyama, T; Ario, K; Fujimoto, M; Kamachi, S; Kawazoe, S; Nakashita, S; Noda, T; Oeda, S; Otsuka, T; Sumida, C; Tabuchi, M, 2012) |
| "Pancreatitis is the most common complication of therapeutic endoscopic retrograde cholangiopancreatography (ERCP), and many pharmacoprophylactic approaches have been suggested, though not without controversy." | 6.77 | Combination of diclofenac plus somatostatin in the prevention of post-ERCP pancreatitis: a randomized, double-blind, placebo-controlled trial. ( Beltsis, A; Chatzimavroudis, G; Dimou, E; Fasoulas, K; Kaltsa, A; Katsinelos, P; Katsinelos, T; Kountouras, J; Paroutoglou, G; Terzoudis, S; Zavos, C, 2012) |
| "Acute pancreatitis is a major adverse event of endoscopic retrograde cholangiopancreatography (ERCP)." | 5.62 | Efficacy of low dose rectal diclofenac for preventing post-endoscopic retrograde cholangiopancreatography pancreatitis: Propensity score-matched analysis. ( Fujii, Y; Horiguchi, S; Kato, H; Matsumi, A; Matsumoto, K; Miyamoto, K; Okada, H; Saragai, Y; Tomoda, T; Tsutsumi, K; Uchida, D; Ueta, E; Yamazaki, T, 2021) |
| "Of the total cohort, 8." | 5.62 | Rectal diclofenac for prevention of post-endoscopic retrograde cholangiography pancreatitis. ( Losada, HF; San Martin, PI; Silva, JA; Troncoso, AI, 2021) |
| "High-dose rectal diclofenac suppository and epinephrine spray on duodenal papilla during endoscopic retrograde cholangiopancreatography (ERCP) may reduce the incidence of post-ERCP pancreatitis." | 5.41 | Randomized trial of high-dose rectal diclofenac suppository and epinephrine spray on duodenal papilla for prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis. ( Ashraf, A; Dar, HA; Javid, G; Khan, MA; Mohammad, S; Shah, A; Sheikh, NA; Singh, B, 2021) |
| "Both diclofenac and tramadol are equally effective in controlling pain in AP with similar safety profile." | 5.34 | Comparison of efficacy of diclofenac and tramadol in relieving pain in patients of acute pancreatitis: A randomized parallel group double blind active controlled pilot study. ( Dhaka, N; Gupta, V; Kochhar, R; Kumar, NS; Muktesh, G; Samanta, J; Samra, T; Sarma, P; Sinha, SK; Yadav, TD, 2020) |
| "We aimed to compare the efficacy of prophylactic, parenterally administered ceftazidime and rectally applied diclofenac sodium for the prophylaxis of post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP)." | 5.24 | Diclofenac sodium versus ceftazidime for preventing pancreatitis after endoscopic retrograde cholangiopancreatography: a prospective, randomized, controlled trial. ( Blažević, I; Bulić, Z; Giljača, V; Hauser, G; Poropat, G; Salkić, N; Štimac, D, 2017) |
| "We carried out a literature search of random controlled trials (RCTs) on preventing post-operative pancreatitis by administration of the anti-inflammatory drugs, indomethacin and diclofenac, following endoscopic retrograde cholangiopancreatography (ERCP)." | 5.22 | Efficacy of Combined Management with Nonsteroidal Anti-inflammatory Drugs for Prevention of Pancreatitis After Endoscopic Retrograde Cholangiography: a Bayesian Network Meta-analysis. ( Du, F; Fan, H; Ren, L; Yang, X; Yuan, W; Zhang, L; Zhang, Y, 2022) |
| "Routine rectal administration of 100 mg of diclofenac or indomethacin was demonstrated to be an effective prevention method to prevent post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis." | 5.22 | The Incidence and Severity of Post-ERCP Pancreatitis in Patients Receiving Standard Administration of NSAIDs: a Systematic Review and Meta-analysis. ( Chen, Z; Guo, X; Kang, X; Lou, L; Lu, Y; Luo, H; Pan, Y; Zhou, Z, 2022) |
| "Prophylaxis with diclofenac given rectally or intramuscularly is an effective option for the management of post-ERCP pancreatitis." | 5.22 | Rectal or intramuscular diclofenac reduces the incidence of pancreatitis afterendoscopic retrograde cholangiopancreatography. ( Ataseven, H; Biyik, M; Çifçi, S; Demir, A; Polat, İ; Uçar, E; Uçar, R, 2016) |
| "We aimed to investigate the preventive effect of oral diclofenac on pancreatitis after ERCP in a multicenter, randomized, prospective, placebo-controlled, double-blind trial." | 5.22 | No Benefit of Oral Diclofenac on Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis. ( Doi, S; Hayashi, T; Hisai, H; Ishiwatari, H; Iwashita, T; Kato, J; Kawakami, H; Kawakubo, K; Matsusaki, S; Ono, M; Sakamoto, N; Sonoda, T; Urata, T; Yasuda, I, 2016) |
| "Combination therapy with udenafil and aceclofenac is not effective for the prevention of post-ERCP pancreatitis." | 5.20 | Oral udenafil and aceclofenac for the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis in high-risk patients: a randomized multicenter study. ( Cheon, YK; Choi, JS; Do, JH; Lee, TY; Oh, HC; Song, TJ, 2015) |
| "To assess the efficacy of intramuscular diclofenac and fluid replacement for prevention of post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis." | 5.14 | Efficacy of intramuscular diclofenac and fluid replacement in prevention of post-ERCP pancreatitis. ( Demirkan, H; Saritas, U; Senol, A, 2009) |
| "This trial shows that rectal diclofenac given immediately after endoscopic retrograde cholangiopancreatography can reduce the incidence of acute pancreatitis." | 5.13 | Role of diclofenac in reducing post-endoscopic retrograde cholangiopancreatography pancreatitis. ( Ehsani Ardakani, MJ; Farzin, H; Khorram, H; Khoshbaten, M; Madad, L; Zali, MR, 2008) |
| "The aim of this study was to determine whether prophylactic oral diclofenac will reduce the incidence and the severity of ERCP-induced pancreatitis, especially in high-risk patients." | 5.12 | Efficacy of diclofenac in the prevention of post-ERCP pancreatitis in predominantly high-risk patients: a randomized double-blind prospective trial. ( Cheon, YK; Cho, KB; Fogel, EL; Lazzell-Pannell, L; Lehman, GA; McHenry, L; Schmidt, S; Sherman, S; Watkins, JL, 2007) |
| "This trial shows that rectal diclofenac given immediately after endoscopic retrograde cholangiopancreatography can reduce the incidence of acute pancreatitis." | 5.10 | Diclofenac reduces the incidence of acute pancreatitis after endoscopic retrograde cholangiopancreatography. ( Carter, R; Evans, S; Imrie, C; Murray, B; O'Suilleabhain, C, 2003) |
| "Diclofenac and indomethacin are the most studied drugs for preventing post-ERCP pancreatitis (PEP)." | 4.95 | Indomethacin and diclofenac in the prevention of post-ERCP pancreatitis: a systematic review and meta-analysis of prospective controlled trials. ( Mohácsi, L; Patai, Á; Patai, ÁV; Solymosi, N, 2017) |
| "Pancreatic stent placement, rectal diclofenac, and bolus administration of somatostatin appear to be most effective in preventing post-ERCP pancreatitis." | 4.93 | Endoscopic and pharmacological treatment for prophylaxis against postendoscopic retrograde cholangiopancreatography pancreatitis: a meta-analysis and systematic review. ( Bulajic, M; Faleschini, G; Panic, N; Vadalà di Prampero, SF, 2016) |
| "In this work, no benefit was obtained with diclofenac plus hydration in reducing the number and severity of cases of post-ERCP pancreatitis nor with the other prophylactic measures." | 4.02 | Hydration with Lactated Ringer's solution combined with rectal diclofenac in the prevention of pancreatitis after endoscopic retrograde cholangiopancreatography. ( Almaraz-Gómez, A; Del Olmo Martínez, ML; Velayos Jiménez, B, 2021) |
| "We evaluated the preventive effect of low-dose diclofenac (25-50 mg) on post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP) by propensity score matching analysis." | 4.02 | Rectally Administered Low-Dose Diclofenac Has No Effect on Preventing Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis: A Propensity Score Analysis. ( Hori, Y; Ikeura, T; Ito, T; Masuda, M; Mitsuyama, T; Miyoshi, H; Naganuma, M; Nakamaru, K; Okazaki, K; Shimatani, M; Takaoka, M; Takaori, A, 2021) |
| "A 50-100 mg rectal dose of diclofenac or indomethacin is recommended for prophylaxis of post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP); however, limited data are available regarding the appropriate dose to prevent PEP in elderly patients." | 4.02 | A 25 mg rectal dose of diclofenac for prevention of post-ERCP pancreatitis in elderly patients. ( Fujiwara, Y; Fukuda, T; Higashimori, A; Ikeda, D; Maeda, N; Maruyama, H; Mizuno, Y; Morimoto, K; Nakamura, Y; Nakatani, M; Watanabe, T, 2021) |
| "In this large patient cohort in a low-risk unit, diclofenac does not seem to reduce the risk of post-ERCP pancreatitis in patients with PSC." | 3.96 | Diclofenac does not reduce the risk of acute pancreatitis in patients with primary sclerosing cholangitis after endoscopic retrograde cholangiography. ( Färkkilä, M; Jokelainen, K; Koskensalo, V; Kylänpää, L; Lindström, O; Rainio, M; Tenca, A; Udd, M, 2020) |
| "rectal diclofenac is a nonsteroidal anti-inflammatory drug (NSAID) that is used to prevent pancreatitis in high-risk patients during endoscopic retrograde cholangiopancreatography (ERCP)." | 3.88 | Rectal diclofenac does not prevent post-ERCP pancreatitis in consecutive high-risk and low-risk patients. ( Almaraz Gómez, A; Del Olmo Martínez, L; Velayos Jiménez, B, 2018) |
| "Objective A 50-100-mg rectal dose of nonsteroidal anti-inflammatory drugs (NSAIDs; diclofenac or indomethacin) has been shown to prevent post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP)." | 3.88 | The Effectiveness of the Rectal Administration of Low-dose Diclofenac for the Prevention of Post-endoscopic Retrograde Cholangiopancreatography Pancreatitis. ( Imai, S; Okuno, M; Sato, H; Shiroko, J; Taguchi, D; Takada, J; Thanabashi, S; Yamaguchi, K, 2018) |
| "The NSAIDs ibuprofen and diclofenac were administered to C57BL/6 mice after induction of pancreatitis with serial injections of cerulein." | 3.88 | Ibuprofen and diclofenac treatments reduce proliferation of pancreatic acinar cells upon inflammatory injury and mitogenic stimulation. ( Bombardo, M; Chen, R; Graf, R; Malagola, E; Rudnicka, A; Sonda, S, 2018) |
| "Our aim was to evaluate the effect of diclofenac in preventing post-ERCP pancreatitis (PEP) in a high-volume, low-PEP-risk ERCP unit." | 3.85 | Diclofenac Does Not Reduce the Risk of Post-endoscopic Retrograde Cholangiopancreatography Pancreatitis in Low-Risk Units. ( Kylänpää, L; Lindström, O; Louhimo, J; Rainio, M; Udd, M, 2017) |
| "High patient body weight was associated with a reduced effect of 100 mg diclofenac for prophylaxis of PEP." | 3.83 | Effect of body weight on fixed dose of diclofenac for the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis. ( Hansen, MB; Jørgensen, LN; Leerhøy, B; Nordholm-Carstensen, A; Novovic, S, 2016) |
| "This controlled cohort study suggests that the implementation of a single dose of 100 mg of diclofenac rectally administered significantly reduces the incidence of post-ERCP pancreatitis in an unselected material of patients with native papilla." | 3.80 | Diclofenac is associated with a reduced incidence of post-endoscopic retrograde cholangiopancreatography pancreatitis: results from a Danish cohort study. ( Hansen, MB; Jørgensen, LN; Leerhøy, B; Nordholm-Carstensen, A; Novovic, S, 2014) |
| "A 34 year old female developed acute pancreatitis after commencing diclofenac for a painful arthropathy." | 3.68 | Pancreatitis associated with diclofenac. ( Edward, N; Khan, IH, 1993) |
| "Post-ERCP pancreatitis is usually mild to moderate 95% times." | 3.01 | Is the Combination of Rectal Diclofenac and Intravenous Ringer Lactate Superior to Individual Therapy for Prophylaxis of Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis: A Prospective, Open-Label, Single-Center Randomized Trial. ( Chandnani, S; Debnath, P; Jain, S; Nair, S; Rathi, P; Thanage, R; Udgirkar, S, 2021) |
| "Acute pancreatitis is a major adverse event of endoscopic retrograde cholangiopancreatography (ERCP)." | 2.90 | Combination of Diclofenac and Sublingual Nitrates Is Superior to Diclofenac Alone in Preventing Pancreatitis After Endoscopic Retrograde Cholangiopancreatography. ( Akimoto, Y; Fujii, M; Harada, R; Hata, H; Kato, H; Kawai, Y; Matsubara, M; Ogawa, T; Okada, H; Takatani, M; Tomoda, T; Ueki, T; Wato, M, 2019) |
| "Fentanyl was given as a rescue analgesic through a patient-controlled analgesia pump." | 2.90 | Pentazocine, a Kappa-Opioid Agonist, Is Better Than Diclofenac for Analgesia in Acute Pancreatitis: A Randomized Controlled Trial. ( Bopanna, S; Garg, PK; Gupta, S; Jain, S; Mahapatra, SJ; Singh, P; Sreenivas, V; Trikha, A, 2019) |
| "Acute pancreatitis is one of the most common complications of endoscopic retrograde cholangiopancreatography (ERCP)." | 2.79 | Effect of diclofenac on the levels of lipoxin A4 and Resolvin D1 and E1 in the post-ERCP pancreatitis. ( Bao, JJ; Ding, H; Hu, C; Liu, XC; Mei, Q; Xu, JM; Zhao, XW, 2014) |
| "Pancreatitis is the most common complication of therapeutic endoscopic retrograde cholangiopancreatography (ERCP), and many pharmacoprophylactic approaches have been suggested, though not without controversy." | 2.77 | Combination of diclofenac plus somatostatin in the prevention of post-ERCP pancreatitis: a randomized, double-blind, placebo-controlled trial. ( Beltsis, A; Chatzimavroudis, G; Dimou, E; Fasoulas, K; Kaltsa, A; Katsinelos, P; Katsinelos, T; Kountouras, J; Paroutoglou, G; Terzoudis, S; Zavos, C, 2012) |
| "Acute pancreatitis is a common complication of endoscopic retrograde cholangiopancreatography (ERCP)." | 2.77 | Low-dose rectal diclofenac for prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: a randomized controlled trial. ( Akiyama, T; Ario, K; Fujimoto, M; Kamachi, S; Kawazoe, S; Nakashita, S; Noda, T; Oeda, S; Otsuka, T; Sumida, C; Tabuchi, M, 2012) |
| "Acute pancreatitis is a major adverse event of endoscopic retrograde cholangiopancreatography (ERCP)." | 1.62 | Efficacy of low dose rectal diclofenac for preventing post-endoscopic retrograde cholangiopancreatography pancreatitis: Propensity score-matched analysis. ( Fujii, Y; Horiguchi, S; Kato, H; Matsumi, A; Matsumoto, K; Miyamoto, K; Okada, H; Saragai, Y; Tomoda, T; Tsutsumi, K; Uchida, D; Ueta, E; Yamazaki, T, 2021) |
| "Of the total cohort, 8." | 1.62 | Rectal diclofenac for prevention of post-endoscopic retrograde cholangiography pancreatitis. ( Losada, HF; San Martin, PI; Silva, JA; Troncoso, AI, 2021) |
| "Acute pancreatitis was observed in 13." | 1.42 | Assessment of Pharmacological Prophylaxis for Acute Pancreatitis Following ERCP in Patients with Choledoholithiasis. ( Kołomecki, K; Łubowska-Pająk, E, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (1.59) | 18.2507 |
| 2000's | 7 (11.11) | 29.6817 |
| 2010's | 37 (58.73) | 24.3611 |
| 2020's | 18 (28.57) | 2.80 |
| Authors | Studies |
|---|---|
| Takaori, A | 1 |
| Ikeura, T | 1 |
| Hori, Y | 1 |
| Ito, T | 1 |
| Nakamaru, K | 1 |
| Masuda, M | 2 |
| Mitsuyama, T | 1 |
| Miyoshi, H | 1 |
| Shimatani, M | 1 |
| Takaoka, M | 1 |
| Okazaki, K | 1 |
| Naganuma, M | 1 |
| Thanage, R | 1 |
| Jain, S | 3 |
| Chandnani, S | 1 |
| Udgirkar, S | 1 |
| Nair, S | 1 |
| Debnath, P | 1 |
| Rathi, P | 1 |
| Dar, HA | 1 |
| Shah, A | 1 |
| Javid, G | 1 |
| Khan, MA | 1 |
| Singh, B | 1 |
| Sheikh, NA | 1 |
| Ashraf, A | 1 |
| Mohammad, S | 1 |
| Park, TY | 2 |
| Kang, H | 2 |
| Choi, GJ | 2 |
| Oh, HC | 3 |
| Du, F | 1 |
| Zhang, Y | 1 |
| Yang, X | 1 |
| Zhang, L | 1 |
| Yuan, W | 1 |
| Fan, H | 1 |
| Ren, L | 1 |
| Kang, X | 1 |
| Guo, X | 2 |
| Chen, Z | 1 |
| Zhou, Z | 1 |
| Luo, H | 1 |
| Lu, Y | 1 |
| Lou, L | 1 |
| Pan, Y | 1 |
| Koshitani, T | 1 |
| Konaka, Y | 1 |
| Ohishi, T | 1 |
| Yasuda, T | 1 |
| Morinushi, T | 1 |
| Mita, M | 1 |
| Nakano, K | 1 |
| Fuki, S | 1 |
| Nakagawa, S | 1 |
| Sakai, H | 3 |
| Iwai, N | 3 |
| Sakagami, J | 3 |
| Okuda, T | 3 |
| Ohara, T | 3 |
| Hattori, C | 3 |
| Taniguchi, M | 3 |
| Oka, K | 3 |
| Hara, T | 3 |
| Tsuji, T | 3 |
| Komaki, T | 3 |
| Kagawa, K | 3 |
| Dohi, O | 3 |
| Yasuda, H | 3 |
| Konishi, H | 3 |
| Itoh, Y | 3 |
| Zhang, ZF | 1 |
| Shimamura, T | 1 |
| Miyahara, K | 1 |
| Takamori, A | 1 |
| Hidaka, H | 1 |
| Ito, Y | 1 |
| Fujimoto, S | 1 |
| Takedomi, H | 1 |
| Tsuruoka, N | 1 |
| Sakata, Y | 1 |
| Eguchi, Y | 1 |
| Node, K | 1 |
| Noda, T | 2 |
| Fujimoto, K | 1 |
| Kumar, NS | 1 |
| Muktesh, G | 1 |
| Samra, T | 1 |
| Sarma, P | 1 |
| Samanta, J | 1 |
| Sinha, SK | 1 |
| Dhaka, N | 1 |
| Yadav, TD | 1 |
| Gupta, V | 1 |
| Kochhar, R | 1 |
| Katoh, T | 1 |
| Kawashima, K | 1 |
| Fukuba, N | 1 |
| Masuda, S | 1 |
| Kobatake, H | 1 |
| Masaki, K | 1 |
| Araki, Y | 1 |
| Kawano, K | 1 |
| Nishi, K | 1 |
| Takenaka, M | 1 |
| Ishihara, S | 1 |
| Kinoshita, Y | 1 |
| Koskensalo, V | 1 |
| Tenca, A | 1 |
| Udd, M | 2 |
| Lindström, O | 2 |
| Rainio, M | 2 |
| Jokelainen, K | 1 |
| Kylänpää, L | 2 |
| Färkkilä, M | 1 |
| Ang, TL | 2 |
| Del Olmo Martínez, ML | 1 |
| Velayos Jiménez, B | 2 |
| Almaraz-Gómez, A | 1 |
| Tomoda, T | 2 |
| Kato, H | 2 |
| Miyamoto, K | 1 |
| Matsumi, A | 1 |
| Ueta, E | 1 |
| Fujii, Y | 1 |
| Saragai, Y | 1 |
| Yamazaki, T | 1 |
| Uchida, D | 1 |
| Matsumoto, K | 1 |
| Horiguchi, S | 1 |
| Tsutsumi, K | 1 |
| Okada, H | 2 |
| Losada, HF | 1 |
| San Martin, PI | 1 |
| Troncoso, AI | 1 |
| Silva, JA | 1 |
| Lehman, GA | 2 |
| Maeda, N | 1 |
| Higashimori, A | 1 |
| Nakatani, M | 1 |
| Mizuno, Y | 1 |
| Nakamura, Y | 1 |
| Ikeda, D | 1 |
| Maruyama, H | 1 |
| Morimoto, K | 1 |
| Fukuda, T | 1 |
| Watanabe, T | 1 |
| Fujiwara, Y | 1 |
| Louhimo, J | 1 |
| Bombardo, M | 1 |
| Malagola, E | 1 |
| Chen, R | 1 |
| Rudnicka, A | 1 |
| Graf, R | 1 |
| Sonda, S | 1 |
| Okuno, M | 1 |
| Shiroko, J | 1 |
| Taguchi, D | 1 |
| Yamaguchi, K | 1 |
| Takada, J | 1 |
| Imai, S | 1 |
| Sato, H | 1 |
| Thanabashi, S | 1 |
| Del Olmo Martínez, L | 1 |
| Almaraz Gómez, A | 1 |
| Hollerbach, S | 1 |
| Lyu, Y | 1 |
| Cheng, Y | 1 |
| Wang, B | 1 |
| Xu, Y | 1 |
| Du, W | 1 |
| Ueki, T | 1 |
| Akimoto, Y | 1 |
| Hata, H | 1 |
| Fujii, M | 1 |
| Harada, R | 1 |
| Ogawa, T | 1 |
| Wato, M | 1 |
| Takatani, M | 1 |
| Matsubara, M | 1 |
| Kawai, Y | 1 |
| Mahapatra, SJ | 1 |
| Bopanna, S | 1 |
| Gupta, S | 1 |
| Singh, P | 1 |
| Trikha, A | 1 |
| Sreenivas, V | 1 |
| Garg, PK | 1 |
| Sethi, S | 1 |
| Sethi, N | 1 |
| Wadhwa, V | 1 |
| Garud, S | 1 |
| Brown, A | 1 |
| Leerhøy, B | 2 |
| Nordholm-Carstensen, A | 2 |
| Novovic, S | 2 |
| Hansen, MB | 2 |
| Jørgensen, LN | 2 |
| Zhao, XW | 1 |
| Bao, JJ | 1 |
| Hu, C | 1 |
| Ding, H | 1 |
| Liu, XC | 1 |
| Mei, Q | 1 |
| Xu, JM | 1 |
| Dumonceau, JM | 1 |
| Andriulli, A | 1 |
| Elmunzer, BJ | 2 |
| Mariani, A | 1 |
| Meister, T | 1 |
| Deviere, J | 1 |
| Marek, T | 1 |
| Baron, TH | 1 |
| Hassan, C | 1 |
| Testoni, PA | 2 |
| Kapral, C | 1 |
| Nicolás-Pérez, D | 1 |
| Castilla-Rodríguez, I | 1 |
| Gimeno-García, AZ | 1 |
| Romero-García, R | 1 |
| Núñez-Díaz, V | 1 |
| Quintero, E | 1 |
| Park, SW | 2 |
| Chung, MJ | 1 |
| Oh, TG | 1 |
| Park, JY | 1 |
| Bang, S | 1 |
| Song, SY | 1 |
| Nicholson, JA | 1 |
| Greenhalf, W | 1 |
| Jackson, R | 1 |
| Cox, TF | 1 |
| Butler, JV | 1 |
| Hanna, T | 1 |
| Harrison, S | 1 |
| Grocock, CJ | 1 |
| Halloran, CM | 1 |
| Howes, NR | 1 |
| Raraty, MG | 1 |
| Ghaneh, P | 1 |
| Johnstone, M | 1 |
| Sarkar, S | 1 |
| Smart, HL | 1 |
| Evans, JC | 1 |
| Aithal, GP | 1 |
| Sutton, R | 1 |
| Neoptolemos, JP | 1 |
| Lombard, MG | 1 |
| Lua, GW | 1 |
| Muthukaruppan, R | 1 |
| Menon, J | 1 |
| Yoshihara, T | 1 |
| Horimoto, M | 1 |
| Kitamura, T | 1 |
| Osugi, N | 1 |
| Ikezoe, T | 1 |
| Kotani, K | 1 |
| Sanada, T | 1 |
| Higashi, C | 1 |
| Yamaguchi, D | 1 |
| Ota, M | 1 |
| Mizuno, T | 1 |
| Gotoh, Y | 1 |
| Okuda, Y | 1 |
| Suzuki, K | 1 |
| Patai, Á | 2 |
| Patai, ÁV | 2 |
| Solymosi, N | 2 |
| Tulassay, Z | 1 |
| Herszényi, L | 1 |
| Shah, T | 1 |
| Zfass, A | 1 |
| Schubert, ML | 1 |
| Saritas, U | 2 |
| Ustundag, Y | 1 |
| Rustagi, T | 1 |
| Njei, B | 1 |
| Lee, TY | 1 |
| Choi, JS | 1 |
| Song, TJ | 1 |
| Do, JH | 1 |
| Cheon, YK | 2 |
| Łubowska-Pająk, E | 1 |
| Kołomecki, K | 1 |
| Hauser, G | 1 |
| Blažević, I | 1 |
| Salkić, N | 1 |
| Poropat, G | 1 |
| Giljača, V | 1 |
| Bulić, Z | 1 |
| Štimac, D | 1 |
| Ishiwatari, H | 1 |
| Urata, T | 1 |
| Yasuda, I | 1 |
| Matsusaki, S | 1 |
| Hisai, H | 1 |
| Kawakami, H | 1 |
| Ono, M | 1 |
| Iwashita, T | 1 |
| Doi, S | 1 |
| Kawakubo, K | 1 |
| Hayashi, T | 1 |
| Sonoda, T | 1 |
| Sakamoto, N | 1 |
| Kato, J | 1 |
| Uçar, R | 1 |
| Biyik, M | 1 |
| Uçar, E | 1 |
| Polat, İ | 1 |
| Çifçi, S | 1 |
| Ataseven, H | 1 |
| Demir, A | 1 |
| Kwek, AB | 1 |
| Song, M | 1 |
| Li, JW | 1 |
| Thurairajah, PH | 1 |
| Vadalà di Prampero, SF | 1 |
| Faleschini, G | 1 |
| Panic, N | 1 |
| Bulajic, M | 1 |
| Mohammad Alizadeh, AH | 1 |
| Abbasinazari, M | 1 |
| Hatami, B | 1 |
| Abdi, S | 1 |
| Ahmadpour, F | 1 |
| Dabir, S | 1 |
| Nematollahi, A | 1 |
| Fatehi, S | 1 |
| Pourhoseingholi, MA | 1 |
| Mohácsi, L | 1 |
| Senol, A | 1 |
| Demirkan, H | 1 |
| Katsinelos, P | 1 |
| Fasoulas, K | 1 |
| Paroutoglou, G | 1 |
| Chatzimavroudis, G | 1 |
| Beltsis, A | 1 |
| Terzoudis, S | 1 |
| Katsinelos, T | 1 |
| Dimou, E | 1 |
| Zavos, C | 1 |
| Kaltsa, A | 1 |
| Kountouras, J | 1 |
| Otsuka, T | 1 |
| Kawazoe, S | 1 |
| Nakashita, S | 1 |
| Kamachi, S | 1 |
| Oeda, S | 1 |
| Sumida, C | 1 |
| Akiyama, T | 1 |
| Ario, K | 1 |
| Fujimoto, M | 1 |
| Tabuchi, M | 1 |
| Murray, B | 1 |
| Carter, R | 1 |
| Imrie, C | 1 |
| Evans, S | 1 |
| O'Suilleabhain, C | 1 |
| Freeman, ML | 1 |
| Oiofinlade, O | 1 |
| Madanick, RD | 1 |
| O'Loughlin, CJ | 1 |
| Barkin, JS | 1 |
| Khoshbaten, M | 1 |
| Khorram, H | 1 |
| Madad, L | 1 |
| Ehsani Ardakani, MJ | 1 |
| Farzin, H | 1 |
| Zali, MR | 1 |
| Cho, KB | 1 |
| Watkins, JL | 1 |
| McHenry, L | 1 |
| Fogel, EL | 1 |
| Sherman, S | 1 |
| Schmidt, S | 1 |
| Lazzell-Pannell, L | 1 |
| Khan, IH | 1 |
| Edward, N | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Rectal Disclofenac Versus Indomethacin for Prevention of Post-ERCP Pancreatitis (DIPPP): A Multicentre, Double-blind, Randomised, Controlled Trial[NCT05947461] | 3,612 participants (Anticipated) | Interventional | 2023-06-01 | Recruiting | |||
| A Randomized Trial Comparing Rectal Indomethacin Alone Versus a Combination of Rectal Indomethacin and Oral Tacrolimus for Post-ERCP Pancreatitis Prophylaxis[NCT05252754] | Phase 3 | 4,874 participants (Anticipated) | Interventional | 2023-01-18 | Recruiting | ||
| Rectal Indomethacin Versus Rectal Indomethacin and Sublingual Nitrate to Prevent Post-ERCP Pancreatitis: a Multicentre, Non-inferiority, Double-blind, Randomised Trial[NCT04425993] | 2,700 participants (Actual) | Interventional | 2020-07-01 | Active, not recruiting | |||
| Endoscopic Retrograde Cholangiopancreatography (ERCP)-Induced and Non-ERCP Induced Acute Pancreatitis: Two Distinct Clinical and Immunological Entities?[NCT02602574] | 66 participants (Anticipated) | Observational | 2018-01-31 | Enrolling by invitation | |||
| Is Needle Knife Fistulotomy An Effective First Step Strategy For All ERCPs?[NCT03698266] | 84 participants (Actual) | Interventional | 2018-11-23 | Completed | |||
| Comparative Evaluation of Standard Prophylaxis Versus Divided-dose NSAIDs or Hybrid NSAID and N-acetylcysteine Therapy for the Prevention of Post-ERCP Pancreatitis[NCT03708458] | Phase 4 | 250 participants (Anticipated) | Interventional | 2017-04-01 | Recruiting | ||
| Combination of Rectal Indomethacin and Pancreatic Duct Stenting Versus Indomethacin Alone in Preventing Post-ERCP Pancreatitis in Patients With Difficult Cannulation[NCT04340687] | 664 participants (Actual) | Observational | 2020-01-01 | Completed | |||
| Risk Factors Related to Post-endoscopic Retrograde Cholangiopancreatography Pancreatitis in High-risk Patients Who Underwent ERCP and Received Prophylactic Rectal Indomethacin[NCT02709421] | 790 participants (Actual) | Observational | 2016-02-29 | Completed | |||
| Effect of Papillary Epinephrine Spraying on Post-ERCP Pancreatitis in Patients Received Rectal Indomethacin: A Multi-center, Double-blind, Randomized Controlled Trial[NCT03057769] | 3,300 participants (Actual) | Interventional | 2017-02-01 | Terminated (stopped due to This study was terminated because of an interim analysis suggesting futility of papillary epinephrine spraying in PEP prevention.) | |||
| [NCT01717599] | 343 participants (Actual) | Interventional | 2012-08-29 | Completed | |||
| A Randomized Double-blinded Trial Comparing the Clinical Efficacy and Pharmacokinetic Parameters of Oral Diclofenac and Intramuscular Diclofenac in Patients With Acute Limb Injuries[NCT03472339] | Phase 4 | 300 participants (Anticipated) | Interventional | 2018-01-15 | Recruiting | ||
| Propofol Sedation During Endoscopic Retrograde Cholangiopancreatography: A Comparison Between Conventional Versus Bispectral Index Guided Approach and Effect of Diclofenac Sodium Along With Topical Pharyngeal Anaesthesia[NCT04860167] | 90 participants (Actual) | Interventional | 2018-09-10 | Completed | |||
| A Randomized Controlled Trial of IV Ketorolac to Prevent Post-ERCP Pancreatitis[NCT02465138] | Phase 4 | 0 participants (Actual) | Interventional | 2023-11-30 | Withdrawn (stopped due to Lack of Funding) | ||
| Comparative Effectiveness Between Rectally Administered Indomethacin and Pancreatic Stenting in the Prevention of Post Endoscopic Retrograde Cholangio-panceaticography (ERCP) Pancreatitis: a Randomized Trial[NCT03713879] | Phase 3 | 1,734 participants (Anticipated) | Interventional | 2019-03-21 | Recruiting | ||
| Timing of Indomethacin Administration for the Prevention of Post-ERCP Pancreatitis (PEP)[NCT02111707] | Phase 4 | 534 participants (Actual) | Interventional | 2014-04-30 | Completed | ||
| [NCT00121901] | Phase 3 | 1,600 participants (Anticipated) | Interventional | 2004-10-31 | Completed | ||
| Prevention of Post-Endoscopic Retrograde Cholangiopancreatography (ERCP) - Induced Pancreatitis Using Aggressive Lactated Ringer's Infusion and/or Rectal Indomethacin[NCT02641561] | Phase 3 | 192 participants (Actual) | Interventional | 2014-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT02641561)
Timeframe: 30 days after ERCP
| Intervention | days (Mean) |
|---|---|
| A (NS+Placebo) | 2.3 |
| B (NS+IND) | 2.2 |
| C (LR+Placebo) | 1.9 |
| D (LR+IND) | 4.3 |
(NCT02641561)
Timeframe: 30 days after ERCP
| Intervention | Participants (Count of Participants) |
|---|---|
| A (NS+Placebo) | 0 |
| B (NS+IND) | 0 |
| C (LR+Placebo) | 0 |
| D (LR+IND) | 0 |
(NCT02641561)
Timeframe: 30 days after ERCP
| Intervention | Participants (Count of Participants) |
|---|---|
| A (NS+Placebo) | 6 |
| B (NS+IND) | 2 |
| C (LR+Placebo) | 2 |
| D (LR+IND) | 1 |
amylase or lipase (NCT02641561)
Timeframe: 30 days after ERCP
| Intervention | Participants (Count of Participants) |
|---|---|
| A (NS+Placebo) | 10 |
| B (NS+IND) | 6 |
| C (LR+Placebo) | 9 |
| D (LR+IND) | 3 |
Imaging may include Computer Tomography (NCT02641561)
Timeframe: 30 days after ERCP
| Intervention | Participants (Count of Participants) |
|---|---|
| A (NS+Placebo) | 0 |
| B (NS+IND) | 1 |
| C (LR+Placebo) | 0 |
| D (LR+IND) | 1 |
bilateral opacities on chest imaging not explained by other lung pathology, respiratory failure not explained by heart failure or volume, and overload and a pulmonary arterial oxygen/fraction of inspired oxygen (PaO2/FiO2) ratio under 300, PaO2/FiO2 ratio is the partial pressure arterial oxygen and fraction of inspired oxygen (NCT02641561)
Timeframe: 30 days after ERCP
| Intervention | Participants (Count of Participants) |
|---|---|
| A (NS+Placebo) | 1 |
| B (NS+IND) | 0 |
| C (LR+Placebo) | 0 |
| D (LR+IND) | 0 |
(NCT02641561)
Timeframe: 30 days after ERCP
| Intervention | Participants (Count of Participants) |
|---|---|
| A (NS+Placebo) | 1 |
| B (NS+IND) | 2 |
| C (LR+Placebo) | 2 |
| D (LR+IND) | 1 |
creatinine > 1.5 milligrams/deciliter (mg/dL) (NCT02641561)
Timeframe: 30 days after ERCP
| Intervention | Participants (Count of Participants) |
|---|---|
| A (NS+Placebo) | 0 |
| B (NS+IND) | 1 |
| C (LR+Placebo) | 0 |
| D (LR+IND) | 0 |
INR > 1.5 (NCT02641561)
Timeframe: 30 days after ERCP
| Intervention | Participants (Count of Participants) |
|---|---|
| A (NS+Placebo) | 0 |
| B (NS+IND) | 0 |
| C (LR+Placebo) | 0 |
| D (LR+IND) | 0 |
Imaging may include Computer Tomography (NCT02641561)
Timeframe: 30 days after ERCP
| Intervention | Participants (Count of Participants) |
|---|---|
| A (NS+Placebo) | 0 |
| B (NS+IND) | 0 |
| C (LR+Placebo) | 0 |
| D (LR+IND) | 0 |
Imaging may include Computer Tomography (NCT02641561)
Timeframe: 30 days after ERCP
| Intervention | Participants (Count of Participants) |
|---|---|
| A (NS+Placebo) | 0 |
| B (NS+IND) | 0 |
| C (LR+Placebo) | 0 |
| D (LR+IND) | 1 |
Imaging may include Computer Tomography (NCT02641561)
Timeframe: 30 days after ERCP
| Intervention | Participants (Count of Participants) |
|---|---|
| A (NS+Placebo) | 0 |
| B (NS+IND) | 0 |
| C (LR+Placebo) | 0 |
| D (LR+IND) | 0 |
(NCT02641561)
Timeframe: 30 days after ERCP
| Intervention | Participants (Count of Participants) |
|---|---|
| A (NS+Placebo) | 6 |
| B (NS+IND) | 2 |
| C (LR+Placebo) | 2 |
| D (LR+IND) | 1 |
positive blood culture (NCT02641561)
Timeframe: 30 days after ERCP
| Intervention | Participants (Count of Participants) |
|---|---|
| A (NS+Placebo) | 0 |
| B (NS+IND) | 0 |
| C (LR+Placebo) | 0 |
| D (LR+IND) | 0 |
> 10% immature neutrophils (band forms). (NCT02641561)
Timeframe: 30 days after ERCP
| Intervention | Participants (Count of Participants) |
|---|---|
| A (NS+Placebo) | 10 |
| B (NS+IND) | 6 |
| C (LR+Placebo) | 9 |
| D (LR+IND) | 3 |
Heart rate > 90 beats per minutes (NCT02641561)
Timeframe: 30 days after ERCP
| Intervention | Participants (Count of Participants) |
|---|---|
| A (NS+Placebo) | 10 |
| B (NS+IND) | 6 |
| C (LR+Placebo) | 9 |
| D (LR+IND) | 3 |
PaCO2 < 4.3 kilopascal (kPa) (32 mmHg) (NCT02641561)
Timeframe: 30 days after ERCP
| Intervention | Participants (Count of Participants) |
|---|---|
| A (NS+Placebo) | 0 |
| B (NS+IND) | 0 |
| C (LR+Placebo) | 0 |
| D (LR+IND) | 0 |
Respiratory rate > 20 breaths per minute (NCT02641561)
Timeframe: 30 days after ERCP
| Intervention | Participants (Count of Participants) |
|---|---|
| A (NS+Placebo) | 10 |
| B (NS+IND) | 6 |
| C (LR+Placebo) | 9 |
| D (LR+IND) | 3 |
Temperature < 36°C(96.8°F) or > 38°C(100.4°F) (NCT02641561)
Timeframe: 30 days after ERCP
| Intervention | Participants (Count of Participants) |
|---|---|
| A (NS+Placebo) | 10 |
| B (NS+IND) | 6 |
| C (LR+Placebo) | 9 |
| D (LR+IND) | 3 |
white blood cell (WBC) count < 4000 cells/mm³ (4 x 109 cells/L) (NCT02641561)
Timeframe: 30 days after ERCP
| Intervention | Participants (Count of Participants) |
|---|---|
| A (NS+Placebo) | 0 |
| B (NS+IND) | 0 |
| C (LR+Placebo) | 0 |
| D (LR+IND) | 0 |
10 reviews available for diclofenac and Pancreatitis
| Article | Year |
|---|---|
Rectal NSAIDs-based combination modalities are superior to single modalities for prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: a network meta-analysis.
Topics: Administration, Rectal; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endoscopi | 2022 |
Efficacy of Combined Management with Nonsteroidal Anti-inflammatory Drugs for Prevention of Pancreatitis After Endoscopic Retrograde Cholangiography: a Bayesian Network Meta-analysis.
Topics: Administration, Rectal; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endoscopi | 2022 |
The Incidence and Severity of Post-ERCP Pancreatitis in Patients Receiving Standard Administration of NSAIDs: a Systematic Review and Meta-analysis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endoscopic Retrograde; Diclofenac | 2022 |
Prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis with a combination of pharmacological agents based on rectal non-steroidal anti-inflammatory drugs: A systematic review and network meta-analysis.
Topics: Administration, Rectal; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endoscopi | 2021 |
What is impact of nonsteroidal anti-inflammatory drugs in the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: a meta-analysis of randomized controlled trials.
Topics: Administration, Rectal; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endoscopi | 2018 |
A meta-analysis on the role of rectal diclofenac and indomethacin in the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis.
Topics: Administration, Rectal; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endoscopi | 2014 |
[Prevention of acute pancreatitis following endoscopic retrograde cholangiopancreatography].
Topics: Acute Disease; Administration, Rectal; Anti-Inflammatory Agents, Non-Steroidal; Catheterization; Cho | 2015 |
Factors Affecting the Efficacy of Nonsteroidal Anti-inflammatory Drugs in Preventing Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis: A Systematic Review and Meta-analysis.
Topics: Administration, Rectal; Anti-Inflammatory Agents, Non-Steroidal; Chi-Square Distribution; Cholangiop | 2015 |
Endoscopic and pharmacological treatment for prophylaxis against postendoscopic retrograde cholangiopancreatography pancreatitis: a meta-analysis and systematic review.
Topics: Administration, Intravenous; Administration, Rectal; Anti-Inflammatory Agents, Non-Steroidal; Cholan | 2016 |
Indomethacin and diclofenac in the prevention of post-ERCP pancreatitis: a systematic review and meta-analysis of prospective controlled trials.
Topics: Administration, Rectal; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endoscopi | 2017 |
21 trials available for diclofenac and Pancreatitis
| Article | Year |
|---|---|
Is the Combination of Rectal Diclofenac and Intravenous Ringer Lactate Superior to Individual Therapy for Prophylaxis of Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis: A Prospective, Open-Label, Single-Center Randomized Trial.
Topics: Administration, Intravenous; Administration, Rectal; Cholangiopancreatography, Endoscopic Retrograde | 2021 |
Randomized trial of high-dose rectal diclofenac suppository and epinephrine spray on duodenal papilla for prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis.
Topics: Administration, Rectal; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endoscopi | 2021 |
Prophylaxis of Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis Using Temporary Pancreatic Stents Versus Rectal Nonsteroidal Anti-inflammatory Drugs: A Randomized Controlled Trial.
Topics: Administration, Rectal; Amylases; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, | 2022 |
Comparison of efficacy of diclofenac and tramadol in relieving pain in patients of acute pancreatitis: A randomized parallel group double blind active controlled pilot study.
Topics: Acute Disease; Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Double-Blind Method; Humans; Pai | 2020 |
Low-dose rectal diclofenac does not prevent post-ERCP pancreatitis in low- or high-risk patients.
Topics: Administration, Rectal; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Cholangiop | 2020 |
Combination of Diclofenac and Sublingual Nitrates Is Superior to Diclofenac Alone in Preventing Pancreatitis After Endoscopic Retrograde Cholangiopancreatography.
Topics: Administration, Sublingual; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, | 2019 |
Pentazocine, a Kappa-Opioid Agonist, Is Better Than Diclofenac for Analgesia in Acute Pancreatitis: A Randomized Controlled Trial.
Topics: Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Dose-Response Relationship, | 2019 |
Effect of diclofenac on the levels of lipoxin A4 and Resolvin D1 and E1 in the post-ERCP pancreatitis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endoscopic Retrograde; Diclofenac | 2014 |
Intramuscular diclofenac for the prevention of post-ERCP pancreatitis: a randomized trial.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endoscopic Retrograd | 2015 |
Can Rectal Diclofenac Prevent Post Endoscopic Retrograde Cholangiopancreatography Pancreatitis?
Topics: Administration, Rectal; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatograp | 2015 |
Oral udenafil and aceclofenac for the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis in high-risk patients: a randomized multicenter study.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-S | 2015 |
Diclofenac sodium versus ceftazidime for preventing pancreatitis after endoscopic retrograde cholangiopancreatography: a prospective, randomized, controlled trial.
Topics: Abdominal Pain; Administration, Intravenous; Administration, Rectal; Adult; Aged; Aged, 80 and over; | 2017 |
No Benefit of Oral Diclofenac on Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis.
Topics: Administration, Oral; Aged; Aged, 80 and over; Amylases; Anti-Inflammatory Agents, Non-Steroidal; Au | 2016 |
Rectal or intramuscular diclofenac reduces the incidence of pancreatitis afterendoscopic retrograde cholangiopancreatography.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endoscopic Retrograde; Diclofenac | 2016 |
Comparison of rectal indomethacin, diclofenac, and naproxen for the prevention of post endoscopic retrograde cholangiopancreatography pancreatitis.
Topics: Administration, Rectal; Adult; Aged; Amylases; Anti-Inflammatory Agents, Non-Steroidal; Biomarkers; | 2017 |
Efficacy of intramuscular diclofenac and fluid replacement in prevention of post-ERCP pancreatitis.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endoscopic Retrograde; Dicl | 2009 |
Combination of diclofenac plus somatostatin in the prevention of post-ERCP pancreatitis: a randomized, double-blind, placebo-controlled trial.
Topics: Aged; Aged, 80 and over; Amylases; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography | 2012 |
Low-dose rectal diclofenac for prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: a randomized controlled trial.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endoscopic Retrograde; Dicl | 2012 |
Low-dose rectal diclofenac for prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: a randomized controlled trial.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endoscopic Retrograde; Dicl | 2012 |
Low-dose rectal diclofenac for prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: a randomized controlled trial.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endoscopic Retrograde; Dicl | 2012 |
Low-dose rectal diclofenac for prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: a randomized controlled trial.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endoscopic Retrograde; Dicl | 2012 |
Diclofenac reduces the incidence of acute pancreatitis after endoscopic retrograde cholangiopancreatography.
Topics: Acute Disease; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endos | 2003 |
Diclofenac reduces the incidence of acute pancreatitis after endoscopic retrograde cholangiopancreatography.
Topics: Acute Disease; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endos | 2003 |
Diclofenac reduces the incidence of acute pancreatitis after endoscopic retrograde cholangiopancreatography.
Topics: Acute Disease; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endos | 2003 |
Diclofenac reduces the incidence of acute pancreatitis after endoscopic retrograde cholangiopancreatography.
Topics: Acute Disease; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endos | 2003 |
Diclofenac reduces the incidence of acute pancreatitis after endoscopic retrograde cholangiopancreatography.
Topics: Acute Disease; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endos | 2003 |
Diclofenac reduces the incidence of acute pancreatitis after endoscopic retrograde cholangiopancreatography.
Topics: Acute Disease; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endos | 2003 |
Diclofenac reduces the incidence of acute pancreatitis after endoscopic retrograde cholangiopancreatography.
Topics: Acute Disease; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endos | 2003 |
Diclofenac reduces the incidence of acute pancreatitis after endoscopic retrograde cholangiopancreatography.
Topics: Acute Disease; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endos | 2003 |
Diclofenac reduces the incidence of acute pancreatitis after endoscopic retrograde cholangiopancreatography.
Topics: Acute Disease; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endos | 2003 |
Diclofenac reduces the incidence of acute pancreatitis after endoscopic retrograde cholangiopancreatography.
Topics: Acute Disease; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endos | 2003 |
Diclofenac reduces the incidence of acute pancreatitis after endoscopic retrograde cholangiopancreatography.
Topics: Acute Disease; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endos | 2003 |
Diclofenac reduces the incidence of acute pancreatitis after endoscopic retrograde cholangiopancreatography.
Topics: Acute Disease; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endos | 2003 |
Diclofenac reduces the incidence of acute pancreatitis after endoscopic retrograde cholangiopancreatography.
Topics: Acute Disease; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endos | 2003 |
Diclofenac reduces the incidence of acute pancreatitis after endoscopic retrograde cholangiopancreatography.
Topics: Acute Disease; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endos | 2003 |
Diclofenac reduces the incidence of acute pancreatitis after endoscopic retrograde cholangiopancreatography.
Topics: Acute Disease; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endos | 2003 |
Diclofenac reduces the incidence of acute pancreatitis after endoscopic retrograde cholangiopancreatography.
Topics: Acute Disease; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endos | 2003 |
Diclofenac reduces the incidence of acute pancreatitis after endoscopic retrograde cholangiopancreatography.
Topics: Acute Disease; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endos | 2003 |
Diclofenac reduces the incidence of acute pancreatitis after endoscopic retrograde cholangiopancreatography.
Topics: Acute Disease; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endos | 2003 |
Diclofenac reduces the incidence of acute pancreatitis after endoscopic retrograde cholangiopancreatography.
Topics: Acute Disease; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endos | 2003 |
Diclofenac reduces the incidence of acute pancreatitis after endoscopic retrograde cholangiopancreatography.
Topics: Acute Disease; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endos | 2003 |
Diclofenac reduces the incidence of acute pancreatitis after endoscopic retrograde cholangiopancreatography.
Topics: Acute Disease; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endos | 2003 |
Diclofenac reduces the incidence of acute pancreatitis after endoscopic retrograde cholangiopancreatography.
Topics: Acute Disease; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endos | 2003 |
Diclofenac reduces the incidence of acute pancreatitis after endoscopic retrograde cholangiopancreatography.
Topics: Acute Disease; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endos | 2003 |
Diclofenac reduces the incidence of acute pancreatitis after endoscopic retrograde cholangiopancreatography.
Topics: Acute Disease; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endos | 2003 |
Diclofenac reduces the incidence of acute pancreatitis after endoscopic retrograde cholangiopancreatography.
Topics: Acute Disease; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endos | 2003 |
Role of diclofenac in reducing post-endoscopic retrograde cholangiopancreatography pancreatitis.
Topics: Acute Disease; Administration, Rectal; Adult; Aged; Amylases; Anti-Inflammatory Agents, Non-Steroida | 2008 |
Role of diclofenac in reducing post-endoscopic retrograde cholangiopancreatography pancreatitis.
Topics: Acute Disease; Administration, Rectal; Adult; Aged; Amylases; Anti-Inflammatory Agents, Non-Steroida | 2008 |
Role of diclofenac in reducing post-endoscopic retrograde cholangiopancreatography pancreatitis.
Topics: Acute Disease; Administration, Rectal; Adult; Aged; Amylases; Anti-Inflammatory Agents, Non-Steroida | 2008 |
Role of diclofenac in reducing post-endoscopic retrograde cholangiopancreatography pancreatitis.
Topics: Acute Disease; Administration, Rectal; Adult; Aged; Amylases; Anti-Inflammatory Agents, Non-Steroida | 2008 |
Efficacy of diclofenac in the prevention of post-ERCP pancreatitis in predominantly high-risk patients: a randomized double-blind prospective trial.
Topics: Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Double-Blind Method; Fema | 2007 |
32 other studies available for diclofenac and Pancreatitis
| Article | Year |
|---|---|
Rectally Administered Low-Dose Diclofenac Has No Effect on Preventing Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis: A Propensity Score Analysis.
Topics: Administration, Rectal; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, End | 2021 |
Rectal administration of low-dose diclofenac does not reduce post-endoscopic retrograde cholangiopancreatography pancreatitis: a propensity score matching analysis.
Topics: Administration, Rectal; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endoscopi | 2023 |
Rectal administration of low-dose diclofenac does not reduce post-endoscopic retrograde cholangiopancreatography pancreatitis: a propensity score matching analysis.
Topics: Administration, Rectal; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endoscopi | 2023 |
Rectal administration of low-dose diclofenac does not reduce post-endoscopic retrograde cholangiopancreatography pancreatitis: a propensity score matching analysis.
Topics: Administration, Rectal; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endoscopi | 2023 |
Rectal administration of low-dose diclofenac does not reduce post-endoscopic retrograde cholangiopancreatography pancreatitis: a propensity score matching analysis.
Topics: Administration, Rectal; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endoscopi | 2023 |
More Evidence Needed on the Combination of Diclofenac and Sublingual Nitrates in Preventing Pancreatitis After Endoscopic Retrograde Cholangiopancreatography.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endoscopic Retrograde; Diclofenac | 2019 |
Risk Factors for Post-Endoscopic Retrograde Pancreatography Pancreatitis: A Retrospective Chart Review in a Regional Hospital in Japan.
Topics: Age Factors; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatogra | 2020 |
Diclofenac does not reduce the risk of acute pancreatitis in patients with primary sclerosing cholangitis after endoscopic retrograde cholangiography.
Topics: Administration, Rectal; Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Case-Contr | 2020 |
Mitigating the risk of post-ERCP pancreatitis: Science and clinical practice.
Topics: Administration, Rectal; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endoscopi | 2020 |
Hydration with Lactated Ringer's solution combined with rectal diclofenac in the prevention of pancreatitis after endoscopic retrograde cholangiopancreatography.
Topics: Administration, Rectal; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatograp | 2021 |
Efficacy of low dose rectal diclofenac for preventing post-endoscopic retrograde cholangiopancreatography pancreatitis: Propensity score-matched analysis.
Topics: Acute Disease; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endoscopic Retrogr | 2021 |
Rectal diclofenac for prevention of post-endoscopic retrograde cholangiography pancreatitis.
Topics: Acute Disease; Adult; Aged; Cholangiography; Cholangiopancreatography, Endoscopic Retrograde; Diclof | 2021 |
A 25 mg rectal dose of diclofenac for prevention of post-ERCP pancreatitis in elderly patients.
Topics: Aged; Cholangiopancreatography, Endoscopic Retrograde; Diclofenac; Humans; Indomethacin; Pancreatiti | 2021 |
Diclofenac Does Not Reduce the Risk of Post-endoscopic Retrograde Cholangiopancreatography Pancreatitis in Low-Risk Units.
Topics: Administration, Rectal; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-St | 2017 |
Ibuprofen and diclofenac treatments reduce proliferation of pancreatic acinar cells upon inflammatory injury and mitogenic stimulation.
Topics: Acinar Cells; Animals; Cell Differentiation; Cell Proliferation; Ceruletide; Cytokines; Diclofenac; | 2018 |
The Effectiveness of the Rectal Administration of Low-dose Diclofenac for the Prevention of Post-endoscopic Retrograde Cholangiopancreatography Pancreatitis.
Topics: Administration, Rectal; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Cholangiop | 2018 |
Rectal diclofenac does not prevent post-ERCP pancreatitis in consecutive high-risk and low-risk patients.
Topics: Administration, Rectal; Adult; Age Factors; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-S | 2018 |
["Indomethacin and diclofenac in the prevention of post-ERCP pancreatitis: a systematic review and meta-analysis of prospective controlled trials"].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endoscopic Retrograde; Diclofenac | 2018 |
Diclofenac is associated with a reduced incidence of post-endoscopic retrograde cholangiopancreatography pancreatitis: results from a Danish cohort study.
Topics: Acute Disease; Administration, Rectal; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cholang | 2014 |
Prophylaxis of post-ERCP pancreatitis: European Society of Gastrointestinal Endoscopy (ESGE) Guideline - updated June 2014.
Topics: Administration, Rectal; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endoscopi | 2014 |
Prophylaxis of post-ERCP pancreatitis: European Society of Gastrointestinal Endoscopy (ESGE) Guideline - updated June 2014.
Topics: Administration, Rectal; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endoscopi | 2014 |
Prophylaxis of post-ERCP pancreatitis: European Society of Gastrointestinal Endoscopy (ESGE) Guideline - updated June 2014.
Topics: Administration, Rectal; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endoscopi | 2014 |
Prophylaxis of post-ERCP pancreatitis: European Society of Gastrointestinal Endoscopy (ESGE) Guideline - updated June 2014.
Topics: Administration, Rectal; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endoscopi | 2014 |
Prophylaxis of post-ERCP pancreatitis: European Society of Gastrointestinal Endoscopy (ESGE) Guideline - updated June 2014.
Topics: Administration, Rectal; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endoscopi | 2014 |
Prophylaxis of post-ERCP pancreatitis: European Society of Gastrointestinal Endoscopy (ESGE) Guideline - updated June 2014.
Topics: Administration, Rectal; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endoscopi | 2014 |
Prophylaxis of post-ERCP pancreatitis: European Society of Gastrointestinal Endoscopy (ESGE) Guideline - updated June 2014.
Topics: Administration, Rectal; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endoscopi | 2014 |
Prophylaxis of post-ERCP pancreatitis: European Society of Gastrointestinal Endoscopy (ESGE) Guideline - updated June 2014.
Topics: Administration, Rectal; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endoscopi | 2014 |
Prophylaxis of post-ERCP pancreatitis: European Society of Gastrointestinal Endoscopy (ESGE) Guideline - updated June 2014.
Topics: Administration, Rectal; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endoscopi | 2014 |
Prophylaxis of post-ERCP pancreatitis: European Society of Gastrointestinal Endoscopy (ESGE) Guideline - updated June 2014.
Topics: Administration, Rectal; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endoscopi | 2014 |
Prophylaxis of post-ERCP pancreatitis: European Society of Gastrointestinal Endoscopy (ESGE) Guideline - updated June 2014.
Topics: Administration, Rectal; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endoscopi | 2014 |
Prophylaxis of post-ERCP pancreatitis: European Society of Gastrointestinal Endoscopy (ESGE) Guideline - updated June 2014.
Topics: Administration, Rectal; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endoscopi | 2014 |
Prophylaxis of post-ERCP pancreatitis: European Society of Gastrointestinal Endoscopy (ESGE) Guideline - updated June 2014.
Topics: Administration, Rectal; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endoscopi | 2014 |
Prophylaxis of post-ERCP pancreatitis: European Society of Gastrointestinal Endoscopy (ESGE) Guideline - updated June 2014.
Topics: Administration, Rectal; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endoscopi | 2014 |
Prophylaxis of post-ERCP pancreatitis: European Society of Gastrointestinal Endoscopy (ESGE) Guideline - updated June 2014.
Topics: Administration, Rectal; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endoscopi | 2014 |
Prophylaxis of post-ERCP pancreatitis: European Society of Gastrointestinal Endoscopy (ESGE) Guideline - updated June 2014.
Topics: Administration, Rectal; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endoscopi | 2014 |
Prophylaxis of post-ERCP pancreatitis: European Society of Gastrointestinal Endoscopy (ESGE) Guideline - updated June 2014.
Topics: Administration, Rectal; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endoscopi | 2014 |
Prophylaxis of post-ERCP pancreatitis: European Society of Gastrointestinal Endoscopy (ESGE) Guideline - updated June 2014.
Topics: Administration, Rectal; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endoscopi | 2014 |
Prophylaxis of post-ERCP pancreatitis: European Society of Gastrointestinal Endoscopy (ESGE) Guideline - updated June 2014.
Topics: Administration, Rectal; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endoscopi | 2014 |
Prophylaxis of post-ERCP pancreatitis: European Society of Gastrointestinal Endoscopy (ESGE) Guideline - updated June 2014.
Topics: Administration, Rectal; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endoscopi | 2014 |
Prophylaxis of post-ERCP pancreatitis: European Society of Gastrointestinal Endoscopy (ESGE) Guideline - updated June 2014.
Topics: Administration, Rectal; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endoscopi | 2014 |
Prophylaxis of post-ERCP pancreatitis: European Society of Gastrointestinal Endoscopy (ESGE) Guideline - updated June 2014.
Topics: Administration, Rectal; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endoscopi | 2014 |
Prophylaxis of post-ERCP pancreatitis: European Society of Gastrointestinal Endoscopy (ESGE) Guideline - updated June 2014.
Topics: Administration, Rectal; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endoscopi | 2014 |
Prophylaxis of post-ERCP pancreatitis: European Society of Gastrointestinal Endoscopy (ESGE) Guideline - updated June 2014.
Topics: Administration, Rectal; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endoscopi | 2014 |
Prophylaxis of post-ERCP pancreatitis: European Society of Gastrointestinal Endoscopy (ESGE) Guideline - updated June 2014.
Topics: Administration, Rectal; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endoscopi | 2014 |
Prophylaxis of post-ERCP pancreatitis: European Society of Gastrointestinal Endoscopy (ESGE) Guideline - updated June 2014.
Topics: Administration, Rectal; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endoscopi | 2014 |
Prophylaxis of post-ERCP pancreatitis: European Society of Gastrointestinal Endoscopy (ESGE) Guideline - updated June 2014.
Topics: Administration, Rectal; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endoscopi | 2014 |
Prophylaxis of post-ERCP pancreatitis: European Society of Gastrointestinal Endoscopy (ESGE) Guideline - updated June 2014.
Topics: Administration, Rectal; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endoscopi | 2014 |
Prophylaxis of post-ERCP pancreatitis: European Society of Gastrointestinal Endoscopy (ESGE) Guideline - updated June 2014.
Topics: Administration, Rectal; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endoscopi | 2014 |
Prophylaxis of post-ERCP pancreatitis: European Society of Gastrointestinal Endoscopy (ESGE) Guideline - updated June 2014.
Topics: Administration, Rectal; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endoscopi | 2014 |
Prophylaxis of post-ERCP pancreatitis: European Society of Gastrointestinal Endoscopy (ESGE) Guideline - updated June 2014.
Topics: Administration, Rectal; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endoscopi | 2014 |
Prophylaxis of post-ERCP pancreatitis: European Society of Gastrointestinal Endoscopy (ESGE) Guideline - updated June 2014.
Topics: Administration, Rectal; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endoscopi | 2014 |
Prophylaxis of post-ERCP pancreatitis: European Society of Gastrointestinal Endoscopy (ESGE) Guideline - updated June 2014.
Topics: Administration, Rectal; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endoscopi | 2014 |
Prophylaxis of post-ERCP pancreatitis: European Society of Gastrointestinal Endoscopy (ESGE) Guideline - updated June 2014.
Topics: Administration, Rectal; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endoscopi | 2014 |
Prophylaxis of post-ERCP pancreatitis: European Society of Gastrointestinal Endoscopy (ESGE) Guideline - updated June 2014.
Topics: Administration, Rectal; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endoscopi | 2014 |
Prophylaxis of post-ERCP pancreatitis: European Society of Gastrointestinal Endoscopy (ESGE) Guideline - updated June 2014.
Topics: Administration, Rectal; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endoscopi | 2014 |
Prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: a cost-effectiveness analysis.
Topics: Administration, Rectal; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endoscopi | 2015 |
Incidence of post-ERCP pancreatitis from direct pancreatic juice collection in hereditary pancreatitis and familial pancreatic cancer before and after the introduction of prophylactic pancreatic stents and rectal diclofenac.
Topics: Administration, Rectal; Adult; Anti-Inflammatory Agents, Non-Steroidal; Biomarkers, Tumor; Cholangio | 2015 |
Nonsteroidal anti-inflammatory drugs for preventing post-ERCP pancreatitis: why rectal and not intramuscular?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endoscopic Retrograde; Diclofenac | 2015 |
[In Process Citation].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endoscopic Retrograde; Diclofenac | 2015 |
25 mg versus 50 mg dose of rectal diclofenac for prevention of post-ERCP pancreatitis in Japanese patients: a retrospective study.
Topics: Administration, Rectal; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Cholangiop | 2015 |
Chemoprevention of Post-ERCP Pancreatitis with Rectal NSAIDs: Does Poking Both Ends Justify the Means?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endoscopic Retrograde; Diclofenac | 2015 |
Per-rectal diclofenac decreases the risk of post-ERCP pancreatitis: What about intramuscular diclofenac?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endoscopic Retrograde; Diclofenac | 2015 |
Assessment of Pharmacological Prophylaxis for Acute Pancreatitis Following ERCP in Patients with Choledoholithiasis.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Bile Duct Diseases; Cholangiopancreatography, | 2015 |
Effect of body weight on fixed dose of diclofenac for the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis.
Topics: Acute Disease; Aged; Body Weight; Cholangiopancreatography, Endoscopic Retrograde; Diclofenac; Femal | 2016 |
Comparative study of strategies for preventing post-ERCP pancreatitis after early precut sphincterotomy for biliary access.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, E | 2016 |
Therapy: can rectal NSAIDs prevent post-ERCP pancreatitis?
Topics: Acute Disease; Administration, Rectal; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatogr | 2012 |
Prevention of post-ERCP pancreatitis: pharmacologic solution or patient selection and pancreatic stents?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endoscopic Retrograde; Diclofenac | 2003 |
Diclofenac reduces the incidence of acute pancreatitis after endoscopic retrograde cholangiopancreatography.
Topics: Acute Disease; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endoscopic Retrogr | 2004 |
Diclofenac reduces the incidence of acute pancreatitis after endoscopic retrograde cholangiopancreatography.
Topics: Acute Disease; Anti-Inflammatory Agents, Non-Steroidal; Cholangiopancreatography, Endoscopic Retrogr | 2005 |
Pancreatitis associated with diclofenac.
Topics: Acute Disease; Adult; Diclofenac; Female; Humans; Pancreatitis | 1993 |